About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

COMPLETEDPhase 2

A Study of Pemetrexed and Folic Acid Given Before Surgery (Neoadjuvant Treatment) to Patients With Rectal Cancer.

A Feasibility Study of Pemetrexed Single Agent and Folic Acid Given as Neoadjuvant Treatment in Patients With Resectable Rectal Cancer

NCT00330915•Eli Lilly and Company

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Rectal Neoplasms

Interventions

pemetrexed

Locations

1

Sweden

Locations (1)

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Gothenburg, Sweden

Key Dates

Start Date

June 1, 2006

Primary Completion Date

June 1, 2008

Completion Date

June 1, 2008

Last Updated

July 21, 2009

Related Studies

RECRUITINGPhase 3

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

NCT06662786

Colorectal Neoplasms

RECRUITINGPhase 1

A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers

NCT06663319

Colorectal NeoplasmsGastrointestinal Neoplasms

RECRUITINGPhase 3

Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)

NCT05239741

Colorectal Neoplasms

Comprehensive Analysis of Gut Microbiota Signatures in Metastatic Colorectal Cancer

NCT07154173

Rectal NeoplasmsColon Neoplasms+2 more

RECRUITINGPhase 2/3

DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition

NCT05770102

MalignancyMalignant Neoplasm+8 more

Changes in Reproductive and Sexual Health in People With Early Onset Colorectal Cancer

NCT04812912

Colorectal CancerColorectal Neoplasms+1 more

View all related studies

Sponsors

Lead Sponsor

Eli Lilly and Company

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 21, 2009Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions